Citations 1
SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAF V600E-mutant mCRC
Bekaii‐Saab, Tanios , Manji, Gulam A. , Fernandez, Kathrine C., Abbattista, Antonello, Zhang, Xiaosong , Bekaii-Saab, Tanios S , Élez, Elena , Kopetz, Scott , Tabernero, Josep , Taı̈eb, Julien , Yoshino, Takayuki , Morris, Van K.
Future Oncology | October 10, 2023 | Volume: 20 | Issue: 11 | Pages: 653-663
